Alkermes PLC ALKS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Alkermes Presents Detailed Positive Results From Vibrance-2 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 2 at SLEEP 2026
-
Alkermes Announces Orphan Drug Designations for Alixorexton in the U.S. and Europe
-
Alkermes to Present New Data on Alixorexton and LUMRYZ® (sodium oxybate) at SLEEP 2026, Highlighting Breadth of Sleep Medicine Research
-
Alkermes to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
-
Alkermes to Showcase Leadership in Psychiatry and Orexin Biology With New Data at the American Society of Clinical Psychopharmacology Annual Meeting
-
Alkermes Showcases Data From Psychiatry Portfolio and Sleep Research into Real World Patient Experience at Spring 2026 Scientific Conferences
-
Alkermes Announces Positive Topline Results From REVITALYZ℠ Phase 3 Study Evaluating LUMRYZ® (sodium oxybate) Extended-Release in Adults With Idiopathic Hypersomnia
-
Alkermes plc Reports First Quarter 2026 Financial Results
Trading Information
- Previous Close Price
- $53.78
- Day Range
- $51.86–53.38
- 52-Week Range
- $25.17–55.67
- Bid/Ask
- $51.00 / $55.00
- Shares Outstanding
- 166.68M
- Market Cap
- $8.66B
- Volume/Avg
- 2M / 2M
Key Statistics
- Price/Earnings (Normalized)
- 30.26
- Price/Sales
- 5.94
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Core
- Total Number of Employees
- 2,050
- Website
- https://www.alkermes.com
Competitors
Valuation
|
Metric
|
ALKS
|
JNJ
|
|---|---|---|
Price/Earnings (Normalized) | 30.26 | 24.91 |
Price/Book Value | 5.25 | 7.92 |
Price/Sales | 5.94 | 6.75 |
Price/Cash Flow | 27.25 | 21.84 |
Price/Earnings
ALKS
JNJ
Financial Strength
|
Metric
|
ALKS
|
JNJ
|
|---|---|---|
Quick Ratio | 1.53 | 0.77 |
Current Ratio | 2.27 | 1.03 |
Interest Coverage | 5.83 | 24.09 |
Quick Ratio
ALKS
JNJ
Profitability
|
Metric
|
ALKS
|
JNJ
|
|---|---|---|
Return on Assets (Normalized) | 8.83% | 13.33% |
Return on Equity (Normalized) | 14.02% | 32.77% |
Return on Invested Capital (Normalized) | 11.10% | 20.14% |
Return on Assets
ALKS
JNJ
Drug Manufacturers - Specialty & Generic Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Merck KGaA ADR
MKKGY
| LOCK|?^@C#@! | LOCK|cB>gR | $69B | |||
| Haleon PLC ADR
HLN
| LOCK|F@H><> | LOCK|C? | $43B | |||
| Teva Pharmaceutical Industries Ltd ADR
TEVA
| LOCK|?$Ch!ZL | LOCK|@F<#% | $38B | |||
| Zoetis Inc Class A
ZTS
| LOCK|!gNyNxgX | LOCK|>? | $32B | |||
| Viatris Inc
VTRS
| LOCK|sM$XyCr | LOCK|B%b | $19B | |||
| Elanco Animal Health Inc
ELAN
| LOCK|?j | LOCK|#P | $12B | |||
| Dr Reddy's Laboratories Ltd ADR
RDY
| LOCK|&fHc^b | LOCK|!N | $11B | |||
| Hims & Hers Health Inc Ordinary Shares - Class A
HIMS
| LOCK|!!mtJ@ | LOCK|>$m | $8B | |||
| Prestige Consumer Healthcare Inc
PBH
| LOCK|WPW&vkc | LOCK|y@f?g | $2B | |||
| Perrigo Co PLC
PRGO
| LOCK|!#sCVc | LOCK|%l< | $1B |
United States